|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency with which the c-myc gene is altered and its correlation with age suggest that it may play a role in the development of breast carcinomas.
|
3014513 |
1986 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have identified a rearranged c-myc gene in DNA from tumour tissue from a patient with an aggressive carcinoma of the breast.
|
2838785 |
1987 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The c-myc gene is amplified in the SW 613-S cell line which was established from a human breast carcinoma.
|
3060796 |
1988 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to elucidate this role by overexpressing cloned myc genes in the human breast carcinoma cell line MCF-7.
|
2668848 |
1989 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Selection of cells with different chromosomal localizations of the amplified c-myc gene during in vivo and in vitro growth of the breast carcinoma cell line SW 613-S.
|
2707103 |
1989 |
|
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Amplification of the c-myc gene has been frequently reported in breast carcinomas.
|
2686529 |
1990 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that, compared to amplification of HER2/NEU, MYC, or INT2 oncogene loci, p53 gene mutations and deletions are the most frequently observed genetic change in breast cancer related to a single gene.
|
1961733 |
1991 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Other potential prognostic markers in breast cancer include amplification of the c-myc gene, and increased expression of both EGFR and p53 protein.
|
8124858 |
1993 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
|
8100712 |
1993 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We propose that in addition to a family history and proliferative atypia, elevated MYC RNA levels during the post-ovulatory phase could potentially be used as a marker of the risk of developing breast cancer.
|
8455947 |
1993 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hormonal progression of breast cancer could be brought about by the enhanced expression of the c-myc gene, with gene amplification and enhanced c-myc mRNA stability being two major mechanisms involved.
|
8432027 |
1993 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A correlation was found between loss of heterozygosity on chromosome 1p32-pter and amplification of the MYC (formerly c-myc) protooncogene (P = 0.003), suggesting that these two genetic events may collaborate during tumor progression in human breast cancer.
|
7913873 |
1994 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results show that in situ hybridization of fine-needle aspiration material is a sensitive method to detect increased expression of the ERBB2 and MYC oncogenes in breast carcinoma.
|
7910618 |
1994 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To attain this goal, amplification of different oncogenes (HER-2/neu, c-MYC and INT-2) was studied in primary tumors of a series of 259 patients with breast cancer (median follow-up of 72 mo).
|
7607564 |
1995 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.
|
8814449 |
1996 |
|
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Oncostatin M-mediated transcriptional suppression of the c-myc gene in breast cancer cells.
|
9187125 |
1997 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics.
|
8993975 |
1997 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The proto-oncogene c-myc is commonly amplified and overexpressed in human breast tumors, and the tumorigenic potential of c-myc overexpression in mammary tissue has been confirmed by both in vitro and in vivo models of breast cancer.
|
9164674 |
1997 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, FISH was used to quantitate HER-2/ neu and c-myc gene amplification in touch preparations of frozen tissue from 100 node-negative breast carcinomas.
|
9237184 |
1997 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we analyzed expression of the c-myc gene using Northern blot and of the p53 and bcl-2 proteins by immuno-histochemistry in 175 breast tumor specimens obtained from patients with operable breast cancer.
|
10567899 |
1999 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data imply that dysregulated MYC gene expression is potentially involved in the pathogenesis of breast cancer, especially by favoring local cell proliferation.
|
10383126 |
1999 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We propose that loss of BIN1 may contribute to breast cancer progression by eliminating a mechanism that restrains the ability of activated MYC to drive cell division inappropriately.
|
10652430 |
2000 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent.
|
11104567 |
2000 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although 9% of the tumours displayed upregulation of c-MYC protein, there was no correlation with beta-catenin overexpression, suggesting that increased beta-catenin expression is not the major cause of c-myc gene activation in breast cancer.
|
10741284 |
2000 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These lines are aneuploid with complex structural rearrangements and have DNA copy-number imbalances involving multiple sites that include amplification of ERBB-2 and MYC proto-oncogenes which are implicated in breast cancer pathogenesis.
|
10639563 |
2000 |